Premium
Design of innovative therapeutics for pharmacoresistant epilepsy: Challenges and needs
Author(s) -
Weaver Donald F.
Publication year - 2013
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.12185
Subject(s) - druggability , computer science , epilepsy , medicine , drug , task (project management) , drug development , neuroscience , intensive care medicine , medical physics , pharmacology , psychology , engineering , systems engineering , biology , biochemistry , gene
Summary Effective therapy for pharmacoresistant epilepsy is an unmet clinical need. Pharmacologically, there are two logical approaches: super‐antiictogenic drugs ( SAID s) or antiepileptogenic agents. However, can either of these agents be successfully designed and developed? Designing SAID s or antiepileptogenics will require applying the techniques of twenty‐first century drug design to this ancient “sacred disease.” Before this task can be effectively realized, five fundamental needs will first have to be addressed: need for antiepileptogenic drug targets, need for druggable targets for SAID s, need for new drug molecule platforms, need for new and relevant animal models, and need for innovative funding strategies.